Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

9.35EUR
11:35am EDT
Change (% chg)

€-0.12 (-1.29%)
Prev Close
€9.47
Open
€9.56
Day's High
€9.56
Day's Low
€9.22
Volume
135,509
Avg. Vol
305,625
52-wk High
€13.68
52-wk Low
€7.05

Latest Key Developments (Source: Significant Developments)

Nicox H1 operating loss narrows to ‍​11.6 million euros
Friday, 8 Sep 2017 01:30am EDT 

Sept 8 (Reuters) - NICOX SA ::‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​.H1 OPERATING LOSS EUR ‍​11.6 MILLION VERSUS LOSS OF EUR 12.7 MILLION YEAR AGO.‍INVESTIGATIONAL NEW DRUG (IND) SUBMISSIONS FOR NCX 470 FOR IOP LOWERING AND NCX 4251 FOR BLEPHARITIS PLANNED FOR H1​.H1 NET LOSS OF THE YEAR EUR 12.2‍​ MILLION VERSUS LOSS OF EUR 24.2 MILLION YEAR AGO.‍BAUSCH + LOMB RESPONDED TO VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% COMPLETE RESPONSE LETTER (CRL) RECEIVED FROM FDA​.REPORTS H1 NO REVENUE VERSUS EUR 9,000 YEAR AGO.NET LOSS FROM CONTINUING OPERATIONS EUR 12.2 MILLION AS OF JUNE 30, 2017, VERSUS NET LOSS OF EUR 12.9 YEAR AGO.‍CASH, CASH EQUIVALENTS OF EUR 20.4 MILLION AS OF JUNE 30, 2017, COMPARED TO EUR 28.9 MILLION ON DECEMBER 31, 2016​.  Full Article

NicOx raises $31 million in private placement of shares
Friday, 18 Aug 2017 02:49am EDT 

Aug 18 (Reuters) - NICOX SA ::ANNOUNCED ON THURSDAY A PRIVATE PLACEMENT OF SHARES TO RAISE EUR 26.25 MILLION (USD 30.97 MILLION).  Full Article

Nicox lists 3.5 million new shares on Euronext Paris
Wednesday, 16 Aug 2017 06:24am EDT 

Aug 16 (Reuters) - EURONEXT::NICOX SA TO LIST 3.5 MILLION NEW SHARES ON EURONEXT PARIS AS OF AUGUST 17; REFERENCE PRICE: EUR 7.5.  Full Article

Nicox announces 26.25 million euros financing
Tuesday, 15 Aug 2017 01:30am EDT 

Aug 15 (Reuters) - NICOX SA ::NICOX ANNOUNCES €26.25 MILLION FINANCING.NICOX SA - ‍RESERVED CAPITAL INCREASE OF ORDINARY SHARES OF COMPANY TO A SPECIFIC CATEGORY OF INVESTORS​.NICOX - ‍TO USE NET PROCEEDS TO FINANCE NICOX'S RESEARCH AND DEVELOPMENT OF PIPELINE CANDIDATES, WORKING CAPITAL.​.  Full Article

Nicox launches capital increase of 597,897 euros following FDA's approval of Zerviate
Friday, 9 Jun 2017 01:45am EDT 

June 9 (Reuters) - NICOX SA ::ANNOUNCED ON THURSDAY ISSUING AND ADMISSION TO TRADING ON THE EURONEXT REGULATED MARKET IN PARIS OF 597,897 NEW SHARES AWARDED TO EXISTING ACIEX SHAREHOLDERS FOLLOWING THE US FDA'S APPROVAL OF ZERVIATE.CAPITAL INCREASE OF NOMINAL AMOUNT OF EUR 597,897.  Full Article

Nicox receives FDA approval of Zerviate1 0.24 pct
Wednesday, 31 May 2017 09:01am EDT 

May 31 (Reuters) - Nicox SA :Nicox receives FDA approval of ZERVIATE1 (cetirizine ophthalmic solution) 0.24%.  Full Article

Nicox receives FDA approval of ZERVIATE1 (cetirizine ophthalmic solution) 0.24%
Wednesday, 31 May 2017 09:00am EDT 

May 31 (Reuters) - NICOX SA ::REG-NICOX RECEIVES FDA APPROVAL OF ZERVIATE1 (CETIRIZINE OPHTHALMIC SOLUTION) 0.24%.‍U.S. PATENT PROTECTION UNTIL AT LEAST 2030​.‍PARTNERING DISCUSSIONS UNDERWAY FOR U.S. COMMERCIALIZATION RIGHTS​.‍TRADING IS EXPECTED TO RECOMMENCE SHORTLY AFTER ISSUANCE OF THIS PRESS RELEASE​.  Full Article

Nicox cash position of 25 million euros as of March 31, 2017
Thursday, 27 Apr 2017 01:30am EDT 

April 27 (Reuters) - Nicox SA : :Cash position of 25 million euros ($27.26 million) as of March 31, 2017.NCX 4251 and NCX 470 on track to enter phase 2.Group records no revenues for Q1 2017.  Full Article

Nicox announces PDUFA date for Zerviate NDA
Tuesday, 11 Apr 2017 01:30am EDT 

Nicox SA : Nicox announces PDUFA date for Zerviate NDA .PDUFA date set for Sept. 8, 2017.  Full Article

Nicox FY operating loss narrows to 1.8 million euros
Friday, 31 Mar 2017 01:30am EDT 

Nicox SA : Cash, cash equivalents and financial instruments of 28.9 million euros as of December 31, 2016, compared to 29.7 million euros on December 31, 2015. . Group recorded a net loss from continued operations of 6.7 million euros as of December 2016, compared to a net loss of 19.8 million euros at same date in 2015 . FY revenue 16,000 euros versus 67,000 euros year ago . FY operating loss of 1.8 million euros versus loss of 20.7 million euros year ago . FY net loss of 19.0 million euros versus loss of 27.9 million euros year ago . H2 2017: expected launch of Vyzulta (TM)in United States by Bausch + Lomb, subject to FDA approval . Q3 2017: potential U.S. FDA approval of ZERVIATE NDA . Q4 2017: start of Phase 2 clinical study for NCX 4251 .Q1 2018: start of Phase 2 clinical study for NCX 470.  Full Article

BRIEF-Nicox H1 operating loss narrows to ‍​11.6 million euros

* ‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​